PRIMARY STUDY
Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial
Key Findings: Resulting data suggests that the use of PEA may produce a synergy with risperidone on autism-related irritability and hyperactivity potentially via its ability to reduce inflammation and glutamate excitotoxicity.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 70
Study Result: Positive
Research Location(s): Iran
Year of Pub: 2018
Cannabinoids Studied: Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Citation: Khalaj M, et al. Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial. J Psychiatr Res. 2018; 103:104-111. doi: 10.1016/j.jpsychires.2018.04.022
Authors: Khalaj M, Saghazadeh A, Shirazi E, Shalbafan MR, Alavi K, Shooshtari MH, Laksari FY, Hosseini M, Mohammadi MR, Akhondzadeh S
